GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chong Kun Dang Pharmaceutical Corp (XKRX:185750) » Definitions » PE Ratio

Chong Kun Dang Pharmaceutical (XKRX:185750) PE Ratio : 6.10 (As of May. 05, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Chong Kun Dang Pharmaceutical PE Ratio?

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-05-05), Chong Kun Dang Pharmaceutical's share price is ₩101900.00. Chong Kun Dang Pharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₩16,696.39. Therefore, Chong Kun Dang Pharmaceutical's PE Ratio for today is 6.10.

Good Sign:

Chong Kun Dang Pharmaceutical Corp stock PE Ratio (=6.33) is close to 10-year low of 5.94

During the past 11 years, Chong Kun Dang Pharmaceutical's highest PE Ratio was 41.33. The lowest was 5.94. And the median was 21.21.

Chong Kun Dang Pharmaceutical's EPS (Diluted) for the three months ended in Dec. 2023 was ₩6,958.29. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₩16,696.39.

As of today (2024-05-05), Chong Kun Dang Pharmaceutical's share price is ₩101900.00. Chong Kun Dang Pharmaceutical's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was ₩16,631.85. Therefore, Chong Kun Dang Pharmaceutical's PE Ratio without NRI ratio for today is 6.13.

During the past 11 years, Chong Kun Dang Pharmaceutical's highest PE Ratio without NRI was 38.96. The lowest was 5.96. And the median was 20.77.

Chong Kun Dang Pharmaceutical's EPS without NRI for the three months ended in Dec. 2023 was ₩6,975.62. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was ₩16,631.85.

During the past 12 months, Chong Kun Dang Pharmaceutical's average EPS without NRI Growth Rate was 157.80% per year. During the past 3 years, the average EPS without NRI Growth Rate was 33.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 27.90% per year.

During the past 11 years, Chong Kun Dang Pharmaceutical's highest 3-Year average EPS without NRI Growth Rate was 113.60% per year. The lowest was 0.30% per year. And the median was 15.10% per year.

Chong Kun Dang Pharmaceutical's EPS (Basic) for the three months ended in Dec. 2023 was ₩6,958.29. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was ₩16,696.39.

Back to Basics: PE Ratio


Chong Kun Dang Pharmaceutical PE Ratio Historical Data

The historical data trend for Chong Kun Dang Pharmaceutical's PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chong Kun Dang Pharmaceutical PE Ratio Chart

Chong Kun Dang Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 19.49 28.07 30.76 13.00 7.84

Chong Kun Dang Pharmaceutical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.00 9.82 8.53 8.40 7.84

Competitive Comparison of Chong Kun Dang Pharmaceutical's PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Chong Kun Dang Pharmaceutical's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chong Kun Dang Pharmaceutical's PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chong Kun Dang Pharmaceutical's PE Ratio distribution charts can be found below:

* The bar in red indicates where Chong Kun Dang Pharmaceutical's PE Ratio falls into.



Chong Kun Dang Pharmaceutical PE Ratio Calculation

The PE Ratio, or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Chong Kun Dang Pharmaceutical's PE Ratio for today is calculated as

PE Ratio=Share Price/Earnings per Share (Diluted) (TTM)
=101900.00/16696.390
=6.1

Chong Kun Dang Pharmaceutical's Share Price of today is ₩101900.00.
Chong Kun Dang Pharmaceutical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩16,696.39.


* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:


There are at least three kinds of PE Ratios used by different investors. They are Trailing Twelve Month PE Ratio, Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio based on inflation-adjusted normalized PE Ratio is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio, the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Chong Kun Dang Pharmaceutical  (XKRX:185750) PE Ratio Explanation

The PE Ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio is positive. Also for stocks with the same PE Ratio, the one with faster growth business is more attractive.

If a company loses money, the PE Ratio becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio divided by the growth ratio. He thinks a company with a PE Ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio of 20, instead of a company growing 10% a year with a PE Ratio of 10.

Because the PE Ratio measures how long it takes to earn back the price you pay, the PE Ratio can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratios are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio.

PE Ratio can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio.


Chong Kun Dang Pharmaceutical PE Ratio Related Terms

Thank you for viewing the detailed overview of Chong Kun Dang Pharmaceutical's PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Chong Kun Dang Pharmaceutical (XKRX:185750) Business Description

Traded in Other Exchanges
N/A
Address
368 Chungjungro-3Ga, Seodaemun-gu, Seoul, KOR, 120-756
Chong Kun Dang Pharmaceutical Corp. is a manufacturer of antibiotics. The company manufactures and distributes over 130 ethical, OTC pharmaceuticals and pharmaceutical active ingredients, primarily focusing on the application of its advanced technologies in fermentation and organic synthesis. The product range includes Rifampicin (antituberculosis), DMCT (raw material for Minocycline), Cephalosporins, 7-ACA and other intermediates of Cephalosporins, Cyclosporin A (immunosuppressant) and Lovastatin (antihyperlipidaemic agent).

Chong Kun Dang Pharmaceutical (XKRX:185750) Headlines

No Headlines